Evidence map›Paper›PMID 35313390›Full record

ArticleJournal of thrombosis and haemostasis : JTH2022

Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.

Philippa Woolley, Anish Tailor, Raakhee Shah, John-Paul Westwood, Marie Scully

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. [Association between vaccination and the risk of immunoglobulin A vasculitis in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
    Article
  3. COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic.Research and practice in thrombosis and haemostasis · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Philippa WoolleyDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.ORCID 0000-0002-6406-3452
Anish TailorDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Raakhee ShahDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
John-Paul WestwoodDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Marie ScullyDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
University College London Hospitals NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune thrombocytopenic purpura (ITP) relapse following vaccination remains poorly reported in the adult population.

objectivesThis report details real world data from the largest single-center cohort of ITP relapse following severe acute respiratory syndrome (SARS-CoV-2) vaccination.

methodsThe vaccination status of 294 patients under active follow-up was reviewed. A total of 17 patients were identified resulting in an incidence of ITP relapse following SARS-CoV-2 vaccination in this cohort of 6.6% and an incidence of newly diagnosed ITP following SARS-CoV-2 vaccination of 1.4%.

resultsPatients were noted to develop marked deviation of platelet count from baseline following vaccination (P =< .0001). Fourteen patients had a prior diagnosis of ITP and median follow-up following diagnosis was 4 years (range 0-45 years). Days from vaccination to presentation ranged from 2-42 (median 14) and the follow-up period was 34 weeks. Fifteen patients (88%) presented with symptoms and all 17 patients developed symptoms during the follow-up period. Nine patients (53%) received a second dose of vaccine during the follow-up period with seven patients (78%) requiring therapeutic support to facilitate second vaccination. Decision to treat patients was multi-factorial and aimed at decreasing bleeding symptoms and obtaining a platelet count >30 × 10

conclusionVaccination of ITP patients continues to have important clinical benefit; however, recommendations for patients who relapse remain lacking. This report outlines the real-world patient outcomes in the era of widespread SARS-CoV-2 vaccination.

Indexed as

COVID-19COVID-19 VaccinesPurpura, Thrombocytopenic, IdiopathicAdultHumansRecurrenceSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19immune thrombocytopeniaplateletsrelapsevaccination

Identifiers

PMID35313390
PMCPMC9115165
OpenAlexW4220928208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.